Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Jefferson City Medical Group

Neither a doctor nor a teaching hospital

Research payments

$1,974,360

768 payments

Through program year 2025, Jefferson City Medical Group is reported as receiving $1,974,360 in research payments, across 768 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $363,211 50
2024 Research $342,206 287
2023 Research $527,435 123
2022 Research $361,698 229
2021 Research $158,174 74
2020 Research $28,367 4
2019 Research $193,269 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Alnylam Pharmaceuticals Inc. $620,827 698 payments
  2. AstraZeneca UK Limited $439,988 2 payments
  3. Novartis Pharmaceuticals Corporation $417,146 4 payments
  4. AbbVie, Inc. $363,873 18 payments
  5. GlaxoSmithKline, LLC. $39,757 7 payments
  6. AstraZeneca Pharmaceuticals LP $28,900 1 payment
  7. Treace Medical Concepts, Inc. $25,762 21 payments
  8. BeiGene, Ltd. $22,350 12 payments
  9. Pfizer Inc. $7,902 3 payments
  10. Almirall LLC $7,855 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $439,988 2 payments
  2. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) $431,253 498 payments
  3. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $299,309 14 payments
  4. A Randomized Double Blind Placebo Controlled 2 Part Adaptive Design Multicenter 12 Week Study to Assess Safety Tolerability and Efficacy of Ljn452 in Patients With Non Alcoholic Steatohepetatis Nash $213,734 2 payments
  5. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 (The Empathy Trial) $148,860 1 payment
  6. Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $118,794 118 payments
  7. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) $61,876 21 payments
  8. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 $54,552 1 payment
  9. M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $49,775 2 payments
  10. A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat $38,698 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record